Legal Investigations into PepGen Spark Investor Concerns Ahead of Deadline

As the deadline for investors of PepGen Inc. approaches, concerns linger for stakeholders with claims against the company. Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently probing potential legal actions, urging affected investors to consider their options.

In an announcement made on July 29, 2025, the law firm highlighted the looming deadline of August 11, 2025, for investors wishing to take on the role of lead plaintiff in a federal securities class action against PepGen. Interested parties who have experienced financial losses exceeding $50,000 between March 7, 2024, and March 3, 2025, are encouraged to reach out to the firm, with specific contact details provided for direct communication.

Background of Allegations

This investigation stems from allegations that PepGen and its executives may have breached federal securities laws. The company is accused of making false and misleading statements and failing to disclose essential information about its product, PGN-EDO51, which was claimed to be less effective and safe than admitted.

The CONNECT2 study, crucial for the relevant FDA approvals, has also been brought into question, with claims emerging that it presented either dangerous conditions or deficiencies that might jeopardize its acceptance. Furthermore, indications arose that PepGen might need to halt the CONNECT2 study, raising red flags about its clinical and regulatory prospects.

Share Price Impact

A series of press releases from PepGen marked significant turns in the company’s stock values, with investor confidence wavering. On July 30, 2024, a release concerning “positive clinical data” sparked temporary hope; however, subsequent remarks from industry analysts underlined disappointment with the results, leading to a substantial fall in share price.

In December 2024, the news of a clinical hold from the FDA regarding the company's IND application further intensified investor fears, contributing to a drop in the stock price once more. Early 2025 saw further turmoil when updates regarding safety concerns and a voluntary pause on the CONNECT2 study were released, exacerbating investor apprehensions and driving prices down substantially.

Potential Legal Recourse

With the announcement of the company's decision to discontinue the development of its DMD programs, now more than ever, investors feel the urgency to act. The lead plaintiff in a securities class action plays a critical role in guiding the lawsuit and addressing the larger class of affected investors.

Faruqi & Faruqi, LLP is not only prioritizing the legal claims regarding PepGen but is also inviting information from a broad range of sources, including whistleblowers and former employees. As the clock ticks towards the deadline, firms such as Faruqi & Faruqi provide vital avenues for investors to discuss their circumstances and potential legal outcomes.

Conclusion

As investigations unfold and investor anxiety builds ahead of the deadline, those impacted by the tumultuous evaluations of PepGen's stocks find themselves at a pivotal juncture. The upcoming August deadline poses both a challenge and an opportunity for affected investors to assert their rights and seek recourse through potential legal action. With the backing of legal experts at Faruqi & Faruqi, those who have faced significant financial losses may reclaim agency in the face of corporate uncertainty.

For updates regarding this evolving situation and more detailed legal advice, interested parties are encouraged to maintain communication with Faruqi & Faruqi, LLP through their established contact channels.